Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 1998 May;36(5):1436-8.
doi: 10.1128/JCM.36.5.1436-1438.1998.

Use of voriconazole in treatment of Scedosporium apiospermum infection: case report

C Girmenia  1 , G Luzi, M Monaco, P Martino
Affiliations
Case Reports

Use of voriconazole in treatment of Scedosporium apiospermum infection: case report

C Girmenia et al. J Clin Microbiol. 1998 May.

Abstract

We report a case of disseminated Scedosporium apiospermum infection in a neutropenic patient with acute myeloid leukemia. Due to progression of the mycosis after 7 days of amphotericin B lipid complex therapy and to high susceptibility of the mold to voriconazole in vitro, the patient was treated with intravenous voriconazole. After a few days of therapy, fever disappeared and skin lesions improved. However, the patient died after 1 month due to intestinal bleeding. Despite a negative outcome, this case seems to indicate a promising role for voriconazole in the treatment of S. apiospermum infections.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
(a) S. apiospermum abdominal skin lesion with purplish-black necrotic center surrounded by large erythema. The fungal lesion worsened despite 7 days of therapy with amphotericin B lipid complex. (b) After 10 days of voriconazole therapy, the erythema disappeared. Only a scab was left.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Barry A L, Brown S D. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother. 1996;40:1948–1949. - PMC - PubMed
    1. Denning D, Del Favero A, Gluckman E, Norfolk D, Ruhnke M, Yonren S, Troke P, Sarantis N. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C: American Society for Microbiology; 1995. UK-109,496, a novel, wide-spectrum triazole derivate for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis, abstr. F80; p. 126.
    1. Dupont B, Denning D, Lode H, Yonren S, Troke P, Sarantis N. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C: American Society for Microbiology; 1995. UK-109,496, a novel, wide-spectrum triazole derivate for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis, abstr. F81; p. 127.
    1. Dworzack D L, Clark R B, Borkowski W J, Jr, Smith D L, Dykstra M, Pugsley M P, Horowitz E A, Connolly T L, McKinney D L, Hostetler M K, Fitzgibbons J F, Galant M. Pseudallescheria boydii brain abscess: association with near-drowning and efficacy of high-dose, prolonged miconazole therapy in patients with multiple abscesses. Medicine. 1989;68:218–224. - PubMed
    1. Espinel-Ingroff A, Dawson K, Pfaller M, Anaissie E, Breslin B, Dixon D, Fothergill A, Paetznick V, Peter J, Rinaldi M, Walsh T. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother. 1995;39:314–319. - PMC - PubMed

Publication types

LinkOut - more resources